KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Receivables (2016 - 2025)

Rigel Pharmaceuticals has reported Receivables over the past 12 years, most recently at $51.8 million for Q4 2025.

  • For Q4 2025, Receivables rose 24.39% year-over-year to $51.8 million; the TTM value through Dec 2025 reached $51.8 million, up 24.39%, while the annual FY2025 figure was $51.8 million, 24.39% up from the prior year.
  • Receivables for Q4 2025 was $51.8 million at Rigel Pharmaceuticals, up from $46.0 million in the prior quarter.
  • Over five years, Receivables peaked at $142.2 million in Q1 2021 and troughed at $3.1 million in Q1 2025.
  • A 5-year average of $31.6 million and a median of $25.5 million in 2023 define the central range for Receivables.
  • Biggest five-year swings in Receivables: surged 1372.0% in 2021 and later tumbled 89.28% in 2022.
  • Year by year, Receivables stood at $15.5 million in 2021, then increased by 29.27% to $20.0 million in 2022, then soared by 52.75% to $30.6 million in 2023, then surged by 36.22% to $41.6 million in 2024, then rose by 24.39% to $51.8 million in 2025.
  • Business Quant data shows Receivables for RIGL at $51.8 million in Q4 2025, $46.0 million in Q3 2025, and $40.0 million in Q2 2025.